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Abstract 
Bipolar Disorder and schizophrenia afflict approximately 2% of the human 
population, more than 12,400,000 people.  When family members, co-workers, and 
care-givers are factored in, more than 10% of the population is directly impacted by 
these medical conditions.  Finding a way to reduce the severity of the symptoms or cure 
these diseases would positively impact a large number of people.  This paper defines 
and differentiates between these two similar-but-different maladies, and explores both 
the traditional courses of treatment as well as the most current research with potential to 
help combat these diseases – especially genetic mapping with the use of neuroimaging.  
Because genetic mapping has been successfully used to treat cancers, applying this 
technique to neurological disorders is the next logical step to take. 
 
Introduction 
Bipolar Disorder (BPD) and Schizophrenia are believed to be among the top ten 
disabilities worldwide and are thought to affect about 2% of the population (1% each). 
Some of the most creative literary minds of the 20th century were known to be afflicted 
with Bipolar Disorder. But while this possible link to creativity is intriguing, the focus of 
this research paper will be to trace the benefits of tried-and-true conventional 
treatments, as well as the promise of novel genetic techniques, as scientists attempt to 
identify the genes responsible for BPD. Currently, the diagnosis of psychiatric disorders 
such as Schizophrenia and Bipolar Disorder is based predominantly on their clinical 
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indices. Several different methods have been investigated as a way to diagnose Bipolar 
Disorder or Schizophrenia with a single genetic test; but there has been inconsistent 
success, so the search continues. While psychiatrists can establish the presence of an 
illness with relative ease, the process to differentiate between possible diagnoses 
based on symptoms of the patient can be very complicated, especially in the early 
phases of Schizophrenia and Bipolar Disorder1. During the process to find the solution, 
many new insights have surfaced. It has been discovered through research that similar 
genes may be responsible for both BPD and Schizophrenia2. In the meantime, patients 
with Bipolar Disorder (and sometimes Schizophrenia) are prescribed lithium. Although 
lithium’s mechanics for alleviating BPD symptoms is not completely known yet, it still 
remains the best treatment today. The discovery of genes causing BPD and other 
psychiatric disorders will almost certainly lead to major advances in understanding their 
pathogenesis, which will then allow researchers to find better and more effective 
treatments3. Most scientists and researchers in this field are interested in identifying the 
biological characteristics of mental illness and have high hopes to soon find the 
underlying susceptible genes for psychiatric disorders. The most important step we can 
take is to understand these disorders, because the disease will be seen at a level that 
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allows for personalized medical treatment. This will potentially lead to improved 
treatment options4. 
What is Bipolar Disorder?  A Primer 
Bipolar Disorder, also known as manic depressive illness, affects approximately 
1% of the population. BPD is also in the top ten leading causes of disability in the 
world5. By its very nature, BPD manifests in numerous parts of the brain, and these 
features can show up across a number of domains. The domains most affected include 
mood, energy, cognition, and personality6. Mounting evidence supports the 
disagreement that, although BPD is clearly not a classic neurodegenerative disorder, it 
is complemented by local brain volumetric diminuitions and cellular atrophy or cellular 
death7. A typical cycle for BPD is a manic cycle that can last for weeks and is then 
followed by weeks to even months of depression, with alternating cycles of mania and 
depression.  The illness as described in the preceding sentence is referred to as Bipolar 
Disorder Type I; but with the cycling of hypomania (as opposed to a manic cycle) and 
depression, the illness is referred to as Bipolar Disorder Type II -- and in these patients 
it appears that the two moods cycle together8. Clinically, BPD II is found to be more 
common in females and has a slightly later onset than males most often diagnosed with 
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BPD I9. Depending on the individual, cycles can occur approximately annually or semi-
annually, once every few months (rapid cycling), weekly to monthly (ultra-rapid cycling); 
or, very rarely, even every 24-48 hours (ultra-ultra-rapid cycling). The cycles of mania 
and depression have very severe symptoms and can become life threatening. 
An individual going through a manic phase is characterized to exhibit an increase 
in energy and the feeling of grandiosity, power, and omnipotence. A manic phase can 
last anywhere from a few days to several weeks and can be hard to distinguish from 
Schizophrenia if auditory hallucinations and paranoia incapacitate the individual. Other 
symptoms of a manic cycle include excessive talking, egocentrism, and impulsivity. In 
manic stages, individuals are more likely to put themselves in dangerous or criminal 
situations. These individuals also propose often improbable plans in excessive 
numbers; thus leading them to feeling overwhelmed by the sheer volume of plans and 
ideas, and thereby decreasing productivity. Certain careers – politics, Science, 
business, and the arts -- benefit from this manic stage10. But because the clinical 
features of ADHD overlap with the symptoms of mania and hypomania, accurate 
diagnosis of mania can be difficult to achieve if the patient has ADHD11. Without a 
manic cycle, the diagnosis of Bipolar Disorder is no longer considered an accurate 
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diagnosis. As described above, these are the characteristics of mania, but depression 
has a completely separate set of criteria to be met12. 
The main characteristics of the depression cycle for someone suffering from 
Bipolar Disorder include intense sadness, hopelessness, anhedonia, deceased energy, 
and a lack of motivation or even caring about their own well-being. The individual in this 
stage can also have trouble focusing on school or work because of the loss of interest 
and lack of energy to care or give effort. Furthermore, there is an increase in feelings of 
worthlessness, worry, and anxiety; thoughts of suicide are probable.  One major way to 
distinguish between the depressive phase of Bipolar Disorder and that of major 
depressive disorder, (a.k.a., unipolar depression) are sleeping and eating habits.  BPD 
patients sleep more and eat more carbs, whereas those suffering from major depressive 
disorder (no manic cycles) have insomnia and eat less.  Although the symptoms are 
easily identifiable; the cause has yet to be pinpointed.  
Variations in the phenomenology of mood can sometimes be attributed to 
additional complications that can frequently mask the correct diagnosis or make a 
diagnosis and treatment harder. These complications can include conditions such as 
substance abuse and anxiety disorders; and these comorbidities have been linked with 
poorer recovery, reduced quality of life, and a heightened risk of suicide13. Anxiety 
disorders (63%) were the most commonly reported comorbidities, followed by 
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behavioral (45%), and substance abuse disorders (37%). Many times, the behavioral 
problems are due to the BPD or other complicating factors. Comorbid anxiety disorders 
present a treatment challenge for clinicians, because the anxiety hampers treatment 
response. BPD comorbid with anxiety really accentuates results of a poorer quality of 
life, elevated suicide risk, and increased health service utilization14. When diagnosing 
someone with Bipolar Disorder, scientists and doctors look at IQ and school 
performance, because high numbers in both can be predictive for Bipolar Disorder15. 
The causes of Bipolar Disorder 
Twin, family, and adoption studies validate the notion that genetic factors play a 
large role in Bipolar Disorder susceptibility. In monozygotic twin studies, the 
concordance rate of BPD is: if one twin has BPD, there is a 60-80% chance that the 
other twin will also have BPD16. Bipolar Disorder has been found to be a polygenic 
disease - a disease linked with environmental factors that contribute to the onset of 
one’s illness and also linked with multiple genes in amalgamation with lifestyles17. Since 
the concordance between monozygotic twins in not 100%, it is a signal that the 
phenotype being studied, in this case, BPD is not based solely on genetics18. Bipolar 
Disorder has always been recognized to be linked with genetics; and because of this 
known fact, numerous studies have been carried out in attempts to map the 
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susceptibility loci. These studies have generated various possible regions with potential 
loci, although none of the studies have identified the exact susceptibility genes. Recent 
meta-analysis of genome scans presented evidence for the most probable location, but 
all established genes established were unpersuasive. It is difficult to locate the specific 
genes causing BPD because of the illness’ inherent intricacy within one’s genetic 
mechanism. Bipolar Disorder is classified to express both heterogeneous and varying 
phenotype expression. In summary, no single study so far has provided strong enough 
conclusions to be considered the ‘best option’ in the advancement in identifying 
vulnerable genes for the traits. It has been agreed upon that a comprehensive approach 
using a number of different methodologies will be needed in the hopes of diagnosing 
and lessing the damages of BPD19.  
 
Treatment of Bipolar Disorder 
 Maintaining Bipolar Disorder can sometimes be achieved through medication. 
These medications can include mood stabilizers and anti-manic drugs such as lithium, 
valproate, and carbamazepine. The administration of antipsychotics and/or 
antidepressants in combination with the mood stabilizers may also be used as a 
treatment strategy. Although some patients’ symptoms can be reduced with medication, 
about one-third of patients do not see the anticipated progress and are still unable to 
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lead normal lives. However, some patients voluntarily stop taking the prescribed 
medications, either because of the side effects from the medicine they take such as 
uncontrollable twitches; or because, similar to someone with an infection who quits 
taking their prescription once they begin to feel better, BPD patients sometimes stop 
taking their medications as soon as they return to their baseline20. 
Lithium 
Mood stabilizers are chemical compounds used to stabilize euthymic patients by 
helping to prevent those patients from experiencing a manic and/or depressed state21. 
Mood stabilizers are used for BPD and Schizophrenia. Mood stabilizers are often 
prescribed along with antidepressants to prevent mood swings. Anticonvulsants such as 
lamotrigine, carbamazephone, valproic acid, or lithium are frequently used as mood 
stabilizers because they treat both problems (not only seizures but also mood swings)22. 
Bolstered by 50 years of successful outcomes, lithium remains as the number one 
choice for treating mood disorders today23. Lithium is very effective and is the most 
widely used anticonvulsant and has been used as a mood stabilizer since the late 
1940s. This is because lithium has been continually studied and consistently shows 
effectiveness as a treatment for some psychiatric disorders. But due to lithium’s 
therapeutic index – the ratio between the dosage of a drug that causes a lethal effect 
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and the dosage that causes therapeutic effects -- close to one, lithium can be very 
difficult to monitor. Lithium’s effectiveness is of major consequence to whether the BPD 
is more genetically-caused or more environmentally-caused.  Research has shown that 
lithium is more effective in people whose psychosomatic ailment follows a periodic 
course, has low rates of comorbidity, lacks rapid cycling, and is accompanied by the 
patient has a family history of Bipolar Disorder. A study on lithium-responders verses 
non-responders has also provided scientists with evidence that treatment must differ for 
the different neuroendocrine systems between responders and non-responders. Signal 
transduction pathways play an important role for the pathophysiology of Bipolar 
Disorder. These signal transduction pathways are also used as the assumed target 
pathway for lithium to start working against the chemicals in the brain triggering the 
disorder24. Over the past twenty-plus years, multiple studies have supported that 
lithium-responsive patients are more likely to have blood-relatives that have also been 
diagnosed with BPD than those who saw no change in mood when taking the lithium. 
Due to the correlation for the lithium-responsive patients, it has been concluded that 
there is “a major gene effect consistent with an autosomal recessive mode of 
inheritance.” With these facts in mind, this observation could eventually lead scientists 
to the answer about the distinction between a Bipolar Disorder phenotype with less 
genetic heterogeneity and a different genotype that is affected more and by stronger 
genetics25’26Scientists are more reliant on those with Bipolar Disorder that have a 
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positive response to lithium, because they believe the answer is very likely to come 
from studying their genetic maps. This is because lithium responders are a collection of 
people with distinctive medical features that correspond to the illness’ “core phenotype.” 
Hence, their family histories have allowed scientists to work within a smaller phenotype 
spectrum. Concluding that one’s response to lithium prophylaxis is hereditary, it was 
determined that lithium responders are a more homogenous subclass of Bipolar 
Disorder. The individuals in this subclass are characterized by having a “strong genetic 
loading” and “a hereditary conduction harmonizing with a major-gene effect.” 
Lithium responders also differ from responders to other mood stabilizers such as 
valproate, carbamazepine, lamotrigine, or olanzapine; lithium-response appears to be 
specific. The first sign of this distinction was seen when anti-manic responses to 
valproate and lithium were noted to be different between patient groups in studies. 
Secondly, the Germany MAP study, a major trial of prophylactic treatment of Bipolar 
Disorder, was able to show that, unlike lithium responders, patients who advanced from 
long-term treatment with carbamazepine had unusual clinical features when compared 
to the lithium responders. Lastly, when comparing lithium responders to lamotrigine 
users, there were differences identified concerning comorbid conditions and their family 
history. Patients that showed a positive response to lamotrigine had higher rates of 
comorbid conditions, especially anxiety, as well as a family history of anxiety disorders. 
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In contrast to lamotrigine responders, lithium responders are characterized to have had 
higher rates of BPD in relatives27. In conclusion, based on genetic heritability, children 
of lithium responders are at a higher risk for developing mainly Bipolar Disorder or 
frequent depression, while offspring of non-responders have displayed a broader and 
less specific array of psychiatric conditions28.  
What is Schizophrenia? 
Schizophrenia is usually described as a disease of young people due to its onset 
primarily in people in their late teens or early twenties. Its victims often feel as if they 
have lost who they are; with reports of ‘losing’ their identity, autonomy, and mental 
capacity. Ten percent of people with Schizophrenia die by suicide. Not only do the 
diagnosed fall victim to this neurodegenerative disease, but also the loved ones around 
the patient. Parents of children with Schizophrenia have described that this disorder 
seems to take the children they knew and turns them into completely different people29. 
Schizophrenia is an incapacitating mental illness characterized by extensive and visible 
brain abnormalities30.  
Just as there are different times people can be diagnosed with cancer 
Schizophrenia can too arise at different times in life. Adult-onset Schizophrenia usually 
occurs during late adolescence and young adulthood. Adult-onset Schizophrenia is also 
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much more common than childhood-onset Schizophrenia31. Childhood-onset 
Schizophrenia is an uncommon and is a more severe form of the disorder characterized 
by the onset of psychosis before the age of 13; the disorder neurobiologically continues 
to degrade as the patient ages into adulthood32. Childhood-onset Schizophrenia causes 
a profound and progressive cortical grey matter damage that continually spreads 
throughout one’s parieto-frontal and parieto-temporal lobes during adolescence. As the 
disorder advances, the degeneration mainly focuses on the prefrontal and temporal 
cortices as children age into young adults33. Neurobiological research suggests that 
child-onset Schizophrenia and adult-onset Schizophrenia share common originating 
factors, although child-onset Schizophrenia is usually considered to be a more severe 
form34. It is an accepted fact that people with established Schizophrenia show brain 
structure irregularities35. When looking at a patient with Schizophrenia overall, a few 
patterns stick out -- such as, exhibiting lower IQ, suffering from memory and language 
impairment, and having poor executive functioning when compared to healthy 
individuals36. 
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Diagnosis of Schizophrenia 
The diagnosis of Schizophrenia is the same for both child-onset and adult-onset 
Schizophrenia. The criteria to be diagnosed with Schizophrenia is outlined in the DSM-
V. The DSM-V requires that two or more characteristic symptoms -- i.e., hallucinations, 
delusions, disorganized speech, disorganized or catatonic behavior, and/or negative 
symptoms -- must be present for at least one month. During the active phase, 
hallucinations, delusions, or disorganized speech must be present. Evidence of the 
disorder must be present for at least six months and must be associated with a 
significant decline in social or occupational functioning. In children and adolescents, 
decline in function may include the failure to achieve age-appropriate levels of 
interpersonal or academic development37. There are trademark phases present in 
Schizophrenia that are very important to recognize when one is making diagnostic and 
therapeutic decisions. Most patients exhibit some degree of deterioration in day-to-day 
functioning. This deterioration is present before the onset of the psychotic symptoms. 
The deterioration phase usually includes social withdrawal or isolation, eccentric or 
bizarre preoccupations, behavior unusual for the patient, new academic failure, 
deteriorating self-care skills, and/or dysphoria38.  
The critical phase for the beginning of Schizophrenia is marked by prominent 
positive symptoms and substantial declines in personal functions. The next step is the 
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recuperative/recovery phase. This occurs after the acute phase and has signs of 
remission of the acute psychosis. Usually, in the recovery phase, there is a several 
month period when the patient still does not continue to function at their base line; both 
negative and positive symptoms can be present39. The final stage is the residual phase. 
At this time in the cycle there are periods recognized between acute phases when the 
affected person does not experience significant positive symptoms40. 
Symptom of and Brain Abnormalities Associated with Schizophrenia 
The signs and symptoms of Schizophrenia are diverse and may include: 
perceptive disorders (hallucinations), inferential thinking (delusions), goal directed 
behavior (avolition), and emotional expression (affective blunting)41. Disorganized 
behavior is also very common, and a patient may express disorganized speech, bizarre 
behavior, and a poor attention span42. None of the above symptoms alone are enough 
to diagnose someone with Schizophrenia; also, none of the above symptoms pertain 
only to Schizophrenia43. Positive and negative symptoms are associated during the 
different phases of Schizophrenia can be distinguished. Positive symptoms are side 
effects such as hallucinations, delusion, and thought disorders. Negative symptoms are 
characterized by being deficits like low energy, lack of emotion, and slowed speech or 
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thought44. Years of research and evidence conclude that Schizophrenia is a progressive 
brain disease45. The molecular mechanism of the brain abnormalities found in 
Schizophrenia remains unclear at this point in time. By trying to understand 
Schizophrenia’s molecular mechanism, scientists could conclude whether the brain 
abnormalities are due to the illness’ state itself, or if it is more tied to genetic risk46. 
 Schizophrenia is known to have extensive gray matter reductions in the affected 
brains; abnormal brain structure is one of the most vigorous biological features of 
Schizophrenia47. Data suggest that the largest decline in volume of the grey matter 
takes place during the first year of onset of the illness48. The most consistent findings 
associate the brain abnormalities with the reduction of grey matter in the prefrontal and 
temporal cortices and the medial temporal lobe structure; but at the same time, there is 
an increase in the lateral ventricular volume. In patients with typical adult-onset 
Schizophrenia, research has shown that progressive brain degeneration of patients’ 
brain tissue is double-fold compared to healthy control subjects. This brain reduction is 
even more severe in cases of childhood-onset Schizophrenia49. One’s hippocampus 
amygdala is also seen to be reduced by the neurodegenerative disease50’51.  Grey 
matter is not the only place differences are found between healthy patients and 
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Schizophrenia patients. Neuroimaging studies have revealed that white matter, too, is 
affected; and the longer one has had the illness, the more pronounced their deficits in 
their white matter52. But in the end, post-mortem studies have revealed that the largest 
impact Schizophrenia has on the brain lies in the dorsolateral prefrontal cortex 
comparative to other cortical regions53. Siblings of those with Schizophrenia have been 
found to have brain scans that reveal that their brain image often has characteristics of 
both Schizophrenic brains and normal, healthy brains. The major difference is the lack 
of brain degeneration compared to those with full-blown Schizophrenia54. 
Causes of Schizophrenia 
A Schizophrenia patient’s multifactorial predispositions that impair 
neurodevelopment are genetics and environmental factors55’56. Schizophrenia has a 
heritability rate of 85%57. The timing of the interaction between environmental factors 
and biologic risk factors facilitates the time of onset, the course of the disease, and 
severity in people with Schizophrenia58. Some studies have found a link between social 
withdrawal at birth and Schizophrenia. Obstetric events are frequently reported to 
facilitate on increased risk for Schizophrenia59.  
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It is now well established that obstetric impediments lead to a person more likely 
to develop Schizophrenia. Three kinds of obstetric complications that lead to the 
increased risks are babies that have fetal growth retardation, fetal perinatal hypoxia, 
and prenatal complications. Lower birth weight, small head circumference, and an 
overall smaller size for the gestational age has been associated with individuals who 
later develop Schizophrenia more so than babies born of an average birth weight. 
Together, these factors point toward fetal growth retardation being an underlying factor 
for Schizophrenia. It has been claimed that fetal growth retardation is facilitated by 
genetic effect, “as mothers with Schizophrenia also have higher rates of low birth weight 
among offspring.”60 Stillbirths and fetal or neonatal deaths occur considerably more 
often among schizophrenic mothers giving birth. Fetal growth retardation has been 
recognized as one of the earliest indicators of the neurodevelopmental course of 
Schizophrenia. Areas of development that are monitored include changes in motor, 
language, and cognitive aptitude from infancy into childhood. It is well known that 
individuals with Schizophrenia are more likely to experience numerous obstetric 
complications involving a lack of or a less-than-needed amount of oxygen reaching the 
individual’s tissues; babies with oxygen deficiency are more apt to develop 
Schizophrenia. The hypothesis is that when oxygen deprivation occurs, this leads to 
reductions in gray-matter volume in one’s cortical and subcortical regions, especially 
the hippocampus. The effects of fetal hypoxia are two-to-three-times greater for people 
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born small for their gestational age. This further complicates the effects of hypoxia, as 
well as shows a connection between genotype and obstetric events61. It is possible that 
there is a stronger correlation than thought between obstetric events and 
Schizophrenia, since not all obstetric complications are recorded on birth records. 
Prenatal complications are also being proved to increase the risk of one’s 
developing Schizophrenia. Such complications can include prenatal stress, intrauterine 
malnutrition, and prenatal infection -- although the list of prenatal risk factors associated 
with Schizophrenia is quickly becoming overbearing to doctors and mothers. The 
reason prenatal complications are so detrimental to the fetus is because they increase 
risks for genetic mutations. Obstetric difficulties undeniably play a role in the etiology of 
Schizophrenia, but the how and the amount of influence these difficulties present is still 
somewhat unknown62. When it comes to the cause of Schizophrenia, no single reason 
has been identified due to the lack of evidence of this complicated neurodevelopment 
disease63. All in all, Schizophrenia is a heterogeneous disorder caused by many 
etiologies64.  
Treatment of Schizophrenia 
Antipsychotic drugs are the course of treatment for people suffering from 
Schizophrenia. These medicines have been around since the mid-1950s. 
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Antipsychotics do not cure the disorder, but rather lessen the symptoms suffered by the 
afflicted. Patients also seem to function better, have a higher quality of life, and have an 
overall better outlook about life. The brand and dose of medicine varies from person-to-
person in order to control the disorder as effectively as possible. The first antipsychotic 
drug was accidentally discovered and happened to be useful in the treatment of 
Schizophrenia. First came Thorazine, and then products such as Haldol, Prolixin, 
Navane, Loxapine, Stelazine, Trilafon, and Mellaril. These drugs are known as 
"neuroleptics - take the neuron" because, although they effectively treat positive 
symptoms, at the same time these medicines can cause “cognitive dulling and 
involuntary movements, among other side effects.” Although the positive symptoms are 
addressed with antipsychotics, negative symptoms are not affected by the medicine. 
Now, as the 21st century commences, gene-mapping research is the best starting point 
for individualized drug development because of the high heritability rates of 
Schizophrenia and because of the up-and-coming genetic mapping techniques being 
applied65. 
Comparing BPD and Schizophrenia 
Both Schizophrenia and Bipolar Disorder symptoms are typically first seen 
between adolescence and mid-twenties. Also, males develop the illnesses earlier than 
females by around 2.5 years. The best differentiating environmental factor relating to 
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Schizophrenia and BPD is that Schizophrenia is more likely to be seen in people with an 
urban upbringing66. Child abuse is highly customary in both, with a strong association 
between auditory hallucinations and childhood traumas in both disorders67. People with 
Schizophrenia seem to have fewer offspring than both BPD and healthy people, and 
BPD people have fewer babies than healthy individuals. Both disorders also have a 
high correlation between those affected and those who smoke tobacco and use illegal 
drugs, with a much stronger correlation between Schizophrenia and drugs. It is 
uncertain whether the drugs contribute to the onset of Schizophrenia or if affected 
persons use drugs to deal with the symptoms, or if it is a combination of both68.  
Returning to the idea that BPD and Schizophrenia are closely related by similar 
genetic mutations, researchers have found a number of genes encoding SNARE 
proteins and vesicle membrane proteins common to both disorders69. Since the 1950’s 
when antipsychotics were first used for Schizophrenia, antipsychotic drugs have now 
been found to also be useful in treating BPD symptoms. Again, this is not surprising 
taking into account the dopamine dysregulation in both disorders70. At the same time, 
mood stabilizers used for BPD are also now being used to treat negative symptoms in 
schizophrenia that are not addressed by antipsychotics71. Copy number variants (CNV), 
when the number of copies of a particular gene fluctuates from person-to-person, have 
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been established to be found in excess in people with Schizophrenia, thus linking 
Schizophrenia with autism, ADHD, and epilepsy. But in contrast, CNVs are not found in 
high number in those afflicted with Bipolar Disorder72.  
Human Genome Project 
The Human Genome Project (HGP) was the basis for dramatic genetic 
advancement. Without the HGP, the idea of personalized medicine would not have ever 
been plausible. The sequence developed by the Human Genome Project positively 
augmented biomedical research73. Using HGP’s broad framework, it is possible for 
scientists to assemble fragmented information into full works of knowledge, useful for 
filling in the blanks about biological structures and functions74.  
Arguably, the greatest impact of genomics is the ability to examine biological 
occurrences in a complete, neutral, and hypothesis-free method. For medicine, 
genomics has allowed for the first efficient approaches to discovering underlying genes 
and cellular pathways for diseases75. Early experiments created epigenomic maps that 
showed the locations of specific DNA modifications, chromatin modifications, and 
protein-binding actions occurring across the human genome, but as technology has 
improved, research is focusing on sequencing different affected human samples in 
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order to study mutations76. The future of genomics includes medical personnel having 
the ability to characterize patients’ germline genomes. The purpose of this is to identify 
strong, projecting transformations in order to allow for presymptomatic counselling, 
search for origins of diseases, and to detect heterozygous carriers. This research is 
currently focused on cancer genomes (by looking at somatic mutations), immune 
repertoires (by looking at B-cell and T-cell receptors), and microbiomes (by connecting 
microbial communities with diseases).  
Research applications will contain characterizing genomes, epigenomes, and 
transcriptomes of humans as well other species77. During meiosis, epigenetic 
information is not completely erased, thereby allowing it to be transmitted through 
multiple replications. Epigenetic markers determine the timing and location of the gene 
expression. Due to epigenetic markers not being fully erased, they can be inherited and 
thus impact an individual’s phenotype, disease vulnerability, and drug response. 
However, these DNA modifications that occur throughout a lifetime are not detectable 
by genotyping and therefore pose challenging limitations on personalized medicine 
based on DNA sequence variations78.  
DNA sequencing is being used more and more frequently in clinical settings in 
order to help doctors prescribe a treatment plan for unclear or undiagnosed diseases. 
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Genomics is also being frequently used in cytogenetics labs. These experiments are 
using DNA microarrays’ high levels of sensitivity to detect clinically important 
chromosomal imbalances. This will help bring about advances in diagnosing and 
evaluating children with idiopathic developmental delays, major intellectual debilitations, 
autism, and birth defects79. By comparing an afflicted person’s genome sequence to 
their parents’ genomes, it will become possible to spot new, lethal mutations on the 
rise. Because genome sequencing has becoming affordable, this process may become 
very customary for parents trying to conceive a baby.  Pediatricians will also use 
genome sequencing to be able to better explain idiopathic disorders in children80. 
Compared to other diseases and disorders, the information related to genetic mapping 
for psychiatric diseases is far less advanced and has a limited scope. Based on the 
progress made towards personalized medicine, it has been determined that larger 
genetic studies are needed in order to understand underlying cellular pathways for 
psychological diseases81. The crucial objective for genetic sequencing is for the process 
to become increasingly simple and cheap so that it can be habitually used as an all-
inclusive apparatus throughout biomedicine82. 
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Potential Genetic Mapping Applications 
Personalized medicine centers on the idea that an individual’s unique genes can 
play a substantial role in tailoring therapies. Characteristics studied include genetic 
alterations, epigenetic modification, clinical symptomatology, observable biomarker 
changes, and environmental factors83. Biomarkers are used as a way for researchers to 
study traits that reveal both genomic and environmental effects, and therefore represent 
the serious physiological state of an individual84. It is anticipated that neuroimaging will 
provide a valuable contribution toward biomarkers guiding personalized medical 
treatment85. Doctors will use genealogy in order to foresee disease susceptibility, create 
accurate diagnoses, and offer patients efficient and advantageous options that please 
both the doctor and patient86. A person’s genes make them either more or less likely to 
respond to different treatment or medications. Genes can also help predict certain side 
effects a patient may experience from the medications87. There have been many 
successful cases using personalized medicine in oncology, but no reported success 
cases for psychology yet88. The future of genetic studies involves finding the link 
between susceptibility to a disorder and the response to a specific treatment, because 
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the cornerstone of this research is the use of genomic biomarkers to exploit advances in 
prevention and treatment89’90. 
 The conjugation of genomics with a drug treatment regimen is known as 
pharmacogentics. Pharmacogenomic involvement has been used to evade adverse 
effects and make sure that correct drug doses are prescribed91. The pharmacogenetics 
of depression, the study of different hereditary variants that determine which 
antidepressant drug should be used, has two goals. The first goal is to use genetic 
testing in order to help psychiatrists make medical decisions so that the quantifiable 
benefits of antidepressant treatment is maximized, while at the same time lessening 
adverse side-effects. Negative side effects include weight gain, suicidal thoughts, and 
erectile dysfunction. The second goal of pharmacogenetics for depression is to discover 
and examine candidate genes recognized to have a role in the pathophysiology of 
depression92.  
Advancement in biomarker development is due to neuroimaging and 
neuroendocrine profiles, proteomics, and metabolomics. Together, these strategies will 
result in tailored antidepressant treatments based on genetic and pathophysiological 
backgrounds. It is already recognized that depressed patients carrying the L allele 
experience better improvement when taking selective serotonin re-uptake inhibitors 
(SSRI) than patients carrying the S alleles. L-allele patients are also known to have 
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better responses to treatment and higher remission rates. All antidepressants are 
broken down in the liver by cytochrome (P450) CYP isoenzymes. Activity of these 
isoenzymes depends on genetic variation and environmental factors like lifestyle and 
age. The difference in the CYP gene activity has led to evolving research for 
personalizing the proper drug dose for a patient93. Identifying poor or ultrafast 
metabolizers has become a vital tool in tailored drug treatment; it has shown promise 
through use in oncology. Mutations in genes can determine a patient’s response to a 
given drug whether positive or negative94.  
Another layer of complexity involves epigenetic mechanisms, which is the study 
of heritable changes in gene activity not triggered by modifications in one’s DNA 
sequence; these changes can stimulate gene expression through chemical chromatin 
modifications95. The inferences of epigenetic modifications for antidepressants showed 
that chronic stress reduces the activity of the enzyme histone deacetylase 5 (HDAC5). 
HDAC5 inhibits gene activity by eradicating acetyl groups from histones, but it was 
found that the effect on HDAC5 is reversed by continuous administration of an 
antidepressant medication96.  
Adverse, early life experiences can end in an imprinted chemical modification 
that continues into adulthood. This is an accepted explanation for the reason why 
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childhood traumas increase one’s risk for mood disorders in adulthood. This fact 
prominently validated that epigenetic modifications are responsive to drug intervention 
and therefore rescindable. With this is mind, and tissue samples available, gene-
environment interactions can now be studied at the molecular level. The study of 
monozygotic twins treated for major depression do not automatically elicit the same 
clinical response pattern because of epigenetic variances in both DNA-methylation 
patterns and histone acetylation accumulation during a lifetime97. Knowing this, it is 
easier for doctors to explain to patients why a medicine or treatment previously used for 
their recurrent major depression may not work the next time around98.  
Placing patients into subgroups based on their genotypes and biomarkers will 
fuel the road towards discovery for new treatments. In order to create these subgroups, 
personalized action for depression will depend on large numbers of people being 
studied as they try out new, multi-tiered procedures that are able to be replicated, and 
by biologically valid experiments in order to see progress and gain more acceptance of 
this practice. Gene function changes depend on both variant nucleotide sequences and 
copy number variations (CNV). Resulting from the completion of the Human Genome 
Project, it became widely known that a person’s genome goes through stages of loss 
and gain of genetic material. Due to this, the weight of each copy number variation’s 
contribution to human maladies is still uncertain. In cases of oncology where genotyping 
has had success, it is recognized that some malignancies are linked to heightened copy 
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numbers of particular genes, but it is difficult to detect the epigenetic changes that have 
been occurring since birth through genotyping99.  
The most relevant topic for clinical research is the discovery and confirmation of 
biomarkers. Specific biomarkers will, in the long run, allow for the match up of the 
specific biomarker and a specific medication; identifying an individual’s pathology is vital 
for this process to work. The extrapolation that a certain antidepressant will work 
effectively for a patient will allow for better treatment and lower costs for treatment, 
because there will be a lack of trial-and-error involved with finding a medicine that works 
for someone100. There are a few different ways researchers are trying to find all of the 
genes, biomarkers, etc., mentioned earlier. One major way researchers are looking for 
these markers are through the development of neuroimaging techniques, such as 
magnetic resonance (MR) or positron emission tomography (PET). The use of these 
tools has been able to answer the basic questions about neuroanatomy, 
neuropathology, neurophysiology, and cognitive neuroscience, thus allowing the 
science to progress as far as it has. An important strategy being used today is to try to 
link the clinical symptoms of Schizophrenia with the causal brain mechanisms101. The 
first approach to this strategy is to assume that current symptoms area caused by a 
certain area of the brain. The backbone to this assumption argues that Schizophrenia 
can be compared to diseases such as neruosyphilis or multiple sclerosis where the 
                                                          
99
 Holsboer, 2008, p. 642 
100
 Holsboer, 2008, p. 642 
101
 Andreasen, 2005, p. 9 
29 
 
disease is amplified by multiple lesions in different areas of the brain causing the clinical 
symptoms. The second approach to this strategy is based on distributed parallel 
processing which theorizes that the fundamental abnormality for psychological 
problems are due to problems in connectivity or wiring in the brain, and that specific 
symptoms reflect specific abnormal wiring. Relevant to this scheme, a solitary well-
placed misconnection or damage to a certain brain circuit can produce a range of inter-
related symptoms because of the intricate feedback loops being the basis of brain 
circuitry102. Science has revealed a short in the brain circuit responsible for filtering 
information taken in by the brain which then forwards the information or stimulant to the 
heteromodal cortex. A problem in this circuit induces feelings of being overloaded with 
information. With the brain being overrun by information, the end results can be 
hallucinations, delusions, disorganized behavior, and the negative symptoms discussed 
earlier. Validity of this proposed model include support by experiments that have 
demonstrated inadequate processing of information in Schizophrenia along with results 
pointing towards abnormal findings in the thalamus and related circuits103. 
Even though genetics is the primary cause for BPD or Schizophrenia, 
epigenetics also play a valid role on the onset of these disorders. Therefore, when 
studying personalized medication, epigenetics cannot be ignored. Epigenetics are 
genetic changes caused by sources that do not alter one’s nucleotide sequence. While 
researching personalized medicine, scientists are realizing the true importance that 
                                                          
102
 Andreasen, 2005, p. 11 
103
 Andreasen, 2005, p. 12 
30 
 
environmental factors play in the role of psychological disorders. Mechanisms for the 
disorder’s causes have to be re-investigated and revised to incorporate the outside 
factors104. Incorporating transcriptomics, proteomics, and all proteins into studies will 
increasingly improve the baseline of information currently available to make well-versed 
resolutions in personalized psychiatry. In conclusion, multidisciplinary approaches are 
being used more frequently and will ultimately be the answer to personalizing medicine. 
Such combinations may inquire whether genes, environmental interactions, and/or 
endopheonotypes will produce distinctive phenotypic expression of the illness, thereby 
increasing the database to draw diagnoses from105. 
Medication (pharmacologic therapy) is not the only part of personalized medicine 
being studied. Other practices that are trying to be introduced to personalized medicine 
are various psychotherapies such as light therapy, deep-brain stimulation, 
electroconvulsive therapy, and transcranial magnetic stimulation. But it is still believed 
that combining neuroimaging with genetics methods will have the largest impact on 
personalized therapy, because the images studied can create measurable biological 
phenotypes. Neuroimaging incorporates genetics, psychiatry, and neuroscience that 
relate genetic variation back to a specific protein function, brain abnormality, and/or 
psychopathology. The two major neuroimaging genetic approaches currently being 
addressed are the identification of imaging changes in a group of people known to have 
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a genetically focused illness and/or the confirmation of effects caused by the specific 
genetic change. A predominantly beneficial facet of describing biological phenotypes 
through imaging is to look at the disease away from self-reported and possibly 
unreliable diagnostics. The aptitude to study in vivo change and change over time for 
psychiatric diseases is vital because of the already identified neuronal plasticity. All in 
all, neuroimaging genetics is showing promising results and may be the necessary 
insight to differentiate between the understanding of the pathophysiology of well-known 
psychiatric disorders by assessing the connection between imaging phenotypes and 
genetic variation106.  
Although neuroimaging has produced reliable data, there are some limitations to 
this type of study. As soon as mediation, like antidepressants, for psychological 
disorders are used work, and the changes in one’s brain can be seen, a cause may be 
revealed. With neuroimaging genetics being a new area of study, there is a higher 
possibility for false positives and imprecise interpretations. There is also some 
skepticism that neuroimaging results being studied are actually showing the functional 
change being investigated. In rebuttal, this type of research emphasizes that MR 
spectroscopy can provide chemical profiles able to tell the difference between brain 
pathologies. 
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Another strategy being used for neuroimaging is the use of positron emission 
tomography/single-photon emission computed tomopraphy. This is more intrusive than 
previously mentioned methods, but has the advantage of permitting in vivo monitoring 
of molecular changes (like receptor or transporter binding density) after therapy. 
Discovery of the biological foundation for distinct symptoms may be just as or more 
useful in understanding the pathophysiology of the illness than coercing a collection of 
symptoms under one biologically likely justification or diagnosis107.  
Going back to the Human Genome project, it is recognized that the vision of P-
med stemmed from that research. P-med is the study of delivering the right drug, at the 
right time, and in the right dose. This is done for an individual patient through the 
integration of all collected data from the patient, especially genomic information. In 
short, the purpose of P-med is to answer the question “which intervention is the best 
one?” by the process of understanding target, characteristic features that lead to a 
certain treatment, treatment management, and use of the least harmful therapy that 
creates the best outcome. P-med is about give-and-take for treatment and side-effects 
of the treatment. As stated before, individualized medicine is most prominent in the 
oncology field with the help of P-med108. Many times, target drugs are found to be 
useful but cannot get past Phase II of testing because they are considered to be 
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unnecessary and not cost-efficient enough109. P-med is based on personalized and 
systematic clarifications of molecular interactions, metabolic pathways, and 
biomarkers110.  
Another recently developed field of study for psychiatry (and other medical 
disciplines) involves characterizing endophenotypes.  It is a captivating endeavor 
because this study may present a less multifaceted ailment predecessor that is more 
feasible for study than the illness syndrome itself. For this process to work, the 
endophenotypes must be connected to a heritable illness common in a population and 
be primarily state independent111. The availability of any additional, objective measure 
can help psychiatrists in the diagnostic process which, of course, improves outcome 
rates and leads to more efficient treatment112. 
The future of personalized medicine in psychiatry essentially echoes ideals that 
are unrealized. At the moment, the field is at the information gathering stage. The 
greatest progress will come from bits and pieces of all the systems from above and will 
inevitably make psychiatry based on biology. But one should not be discouraged at the 
lack of positive information received thus far, because the newest applications including 
imaging genomics, show promise in personalizing medicine113. Personalized medicine 
will ensure that the most effective treatment will be used from patient-to-patient and will 
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have a large impact on reducing the cost for medical treatment. Personalized medicine 
is proclaimed to be the major transformative milestone needed to improve health 
care114. 
Difficulties 
As good as genomics sounds, and despite the endless possibilities of these 
studies, there are still a few shortcomings to be overcome with the methods. 
Individualized medicine touches on ethical boundaries for balancing autonomy with 
resource distribution115. When embarking on the journey to personalize medicine, 
citizen panels had shared expectations for results of improved care116. These panels 
expected increased public awareness and education to increase confidence in the use 
of the technology. This education would include counseling services to help patients 
through the process and pointing out many more options available to them for their 
treatment. At the same time, there is a fear of having too many options, and there is the 
concern that patients’ access to treatment options can become limited. Another worry 
comes from ethical issues as to when to accept the fact that there are no longer any 
plausible options left, but the individualized medicine may extend the inevitable, how 
long should the treatment continue? This issue occurs now, but it is feared that it can 
become more complicated with more options. In the end, the panels agreed that the 
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treatment decisions of the patient should, at the end of the day, be left to the patient, 
because the treatment might offer the patient hope117.  
Conclusion 
Bipolar Disorder and Schizophrenia afflict approximately 2 % of the population 
worldwide.  Because these conditions can be very debilitating to both the victim and 
those close to them, discerning the cause would benefit an even larger percentage of 
the population.  The most recent research focuses on finding the causes of BPD and 
Schizophrenia using genetic mapping and brain scans.  To date, no underlying cause 
has yet been found, and no specific gene has been conclusively identified.  Lithium 
remains the best treatment for BDP for now, and it may also be useful for 
Schizophrenia.  Anti-psychotics work best for Schizophrenia.  Lithium is an anti-
convulsant as well, and most anti-convulsants double as mood stabilizers.  Correct 
diagnoses of BPD versus Schizophrenia or major depression will also result in more 
effective treatment regiments.  At this time doctors can readily identify a psychological 
impairment, but have difficulty differentiating between the maladies without brain scans 
and/or genetic mapping.  Unfortunately, much more research is necessary to enable 
these diagnoses.  In addition to the genetic information that can be used for diagnoses, 
environmental factors and comorbidity also play major roles in the timing, the onset, 
and the severity of both BPD and Schizophrenia. Anxiety and drug use hide the 
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symptoms and make diagnoses even more difficult to pinpoint. The new wave of 
genetic research is showing great promise in cancer treatment, and will undoubtedly 
soon also benefit victims of psychological disorders and their families. 
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